Skip to main content
MBX logo

MBX · MBX Biosciences, Inc.

Track MBX — free
$53.12 -2.82 (-5.04%) At close · Nov 16
Market Cap
$2.64B
Shares
49.66M
Volume · Nov 16 391.31K Avg daily vol (3M) 525.58K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$53.12 Open$55.45 Day$52.90–56.95 52W close$25.61–70.70 Avg vol 30d567K Short int4.3M · 8.6% of shares · 7.9d Short vol55% Last earningsNov 9, 2026 DataSep 2024–Nov 2026 Filing10-Q · Nov 9

Up next

Mar 11, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 10
Investor event
Canvu Paratide trial underway ahead of 4291 data

MBX Biosciences started the phase three Canvu Paratide study and plans a C1 data disclosure for 4291, which showed 7% weight loss at eight weeks; cash runway guidance extends into 2029.

5 source passages
I'm really pleased to be joined again this year by MBX Biosciences. And now, as we are in Q4, we've started the phase three study of Canvu Paratide in chronic HP. The milestone coming up for 4291 is, you're exactly right, is the unblinding of the study, and specifically with a focus on cohort C1. And we had 7% weight loss at eight weeks. Cash Runway, our guidance is the same and has been consistent over the last few quarters, and that's into 2029. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash Funds Operations Into 2029 Despite Wider Net Loss

MBX Biosciences reported $481.6 million in cash, cash equivalents and marketable securities at September 30, 2026, expecting existing resources to fund operations into 2029. Nine-month net loss was $123.0 million, versus $64.9 million in 2025.

Net loss $62.42M Diluted EPS -$1.29
Read from the MD&A section
2 source passages
We had cash, cash equivalents and marketable securities of $481.6 million and $373.7 million as of September 30, 2026 and December 31, 2025, respectively. We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Our net losses were $123.0 million and $64.9 million for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 9
Current report 8-K
Phase 3 trial underway with $481.6 million funding runway into 2029

MBX Biosciences began enrollment in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide. Cash and investments were $481.6 million at September 30, 2026, expected to fund operations into 2029; third-quarter net loss was $62.4 million.

Financial results, Regulation FD disclosure
3 source passages
Pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway: In August 2026, MBX announced the dosing of the first patient in its pivotal Phase 3 oPTimize trial. As of September 30, 2026, MBX had cash, cash equivalents and marketable securities of $481.6 million, which reflects net proceeds of $97.6 million from the sale of common stock under the Company’s at-the-market (ATM) sales agreement. Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029. Net Loss: Net loss for the three months ended September 30, 2026, was $62.4 million compared to a net loss of $21.6 million for the same period in 2025. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 20
Director or officer change, or executive pay

MBX Biosciences appointed Peter Radovich as an independent director and set the board at eight directors. His initial compensation includes a non-qualified stock option for 18,200 shares.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$145.12M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$481.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.0%
Year over year · more shares
Price change (1Y)
+114.3%
Trailing year
Short interest
8.6%
Latest settlement · 7.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +14%
above
Price vs 50-day avg −4%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 61%
mid-range
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +67%
trailing
YTD return +68%
this year
Relative strength +68%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $56 › 200d $46 — 50d above 200d
Institutional flow Distributing
-12% holders QoQ · +32 funds added
Insider flow Distributing
Net -$288.4K over 90 days · 100% sells
Short interest Falling
8.63% of shares out · ▼ -3.1% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
154 holders — mid 2-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Fair
EPS growth +59%
Y/Y
Free cash flow $-81.9M
Quant / Vol
risk profile
Very High
Volatility 77%
annualized · 1-yr
Max drawdown −38%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+14% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
61% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $56 › 200d $46 — 50d above 200d
Institutional flow Distributing
-12% holders QoQ · +32 funds added
Insider flow Distributing
Net -$288.4K over 90 days · 100% sells
Short interest Falling
8.63% of shares out · ▼ -3.1% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
154 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $26 Now $53 · 61% Range high $71
vs 200-day avg +14% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MBX
MBX Biosciences, Inc.
this stock
$2.64B +68.4% — — 8.6%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$87.10B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
154
% held
60.0%
Net QoQ
-25.7M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
212
View
Short & Settlement
Short Interest Falling
Shares short
4.3M
Days to cover
7.9d
Change
-137.7K sh
View
Short Volume
Short vol %
55%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$4.9K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
43.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$288.4K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-87.0M
EPS diluted
$-2.38
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
29

MBX Biosciences started the phase three Canvu Paratide study and plans a C1 data disclosure for 4291, which showed 7% weight loss at eight weeks; cash runway guidance extends into 2029.

View
Proposed Sales
Value
$268.2K
Shares
4.9K
Filed
Nov 10, 2026
View
Exempt Offerings
Offering
$115.2M
Filed
Nov 18, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
MBX Biosciences Reports Third Qua…
Published
Nov 9, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
MBX -1.7% +1.2% +66.6% -4.9% +68.4%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -0.1% +4.7% +68.0% -2.8% +59.9%
Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 150 filings 145 filers Visit website Investor relations